{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:19:42Z","timestamp":1785439182192,"version":"3.56.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This case report retrospectively evaluated the diagnosis and treatment of a multiple myeloma (MM) patient with early relapse in the central nervous system (CNS) post autologous hematopoietic stem cell transplantation (AHSCT). We also performed a literature review of treatment options for patients with CNS myeloma. The patient was diagnosed with isolated CNS relapse of multiple myeloma one month after AHSCT, without other extramedullary lesions and with normal blood, urine, and bone marrow profiles. The patient responded better to combination therapy involving doxorubicin liposomes and a triple intrathecal injection of dexamethasone plus methotrexate plus cytarabine. However, regimens based on the daratumumab, pomalidomide, ixazomib, and selinexor failed to achieve sustained remission in this patient. Seventeen months after experiencing CNS relapse, the patient died because of disease progression. Currently, there is no standard treatment strategy for CNS myeloma and the overall prognosis is still poor.<\/jats:p>","DOI":"10.3389\/fonc.2025.1628297","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:09:56Z","timestamp":1751954996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.ijc_560_20","article-title":"Central nervous system involvement in multiple myeloma: experience from a tertiary cancer center and review of literature","author":"Jain","year":"2023","journal-title":"Indian J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.08.010","article-title":"Myelomatous involvement of the central nervous system","volume":"16","author":"Paludo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1006-7795.2023.01.024","article-title":"Clinical characteristics and prognostic analysis of multiple myeloma involving central nervous system","volume":"44","author":"Jia","year":"2023","journal-title":"Shoudu Yi Ke Da Xue Xue Bao"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-4130.2023.06.024","article-title":"Clinical characteristics analysis of multiple myeloma involving central nervous system: a report of 5 cases","volume":"44","author":"Zhang","year":"2023","journal-title":"Int J Lab Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-8348.2021.02.009","article-title":"Multiple myeloma involving central nervous system infiltration: a report of 7 cases","volume":"50","author":"Cai","year":"2021","journal-title":"Chongqing Med J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1004-2806.2017.05.014","article-title":"Clinical analysis of 8 multiple myeloma patients with central nervous system invaded","volume":"30","author":"Fengkuan","year":"2017","journal-title":"J Clin Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17717","article-title":"A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival","volume":"195","author":"Yamashita","year":"2021","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.934240","article-title":"Central nervous system myeloma and unusual extramedullary localizations: real life practical guidance","volume":"12","author":"Sammartano","year":"2022","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/bjh.17343","article-title":"Thiotepa intrathecal injections for myelomatous central nervous system involvement","volume":"193","author":"Claudel","year":"2021","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1885","article-title":"Case report of bone marrow-sparing proton therapy craniospinal irradiation for central nervous system myelomatosis","volume":"9","author":"Kauffmann","year":"2017","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101465","article-title":"Advances in the treatment of extramedullary disease in multiple myeloma","volume":"22","author":"Li","year":"2022","journal-title":"Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13054","article-title":"Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis","volume":"45","author":"Oka","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.reth.2022.05.007","article-title":"Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement","volume":"21","author":"Zhang","year":"2022","journal-title":"Regener Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1072490","article-title":"Case reports: central nervous system involvement in patients with newly diagnosed multiple myeloma","volume":"14","author":"Liu","year":"2023","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/j.clml.2018.07.229","article-title":"The daratumumab crosses the blood brain barrier","volume":"18","author":"Vercruyssen","year":"2018","journal-title":"Clin Lymph Myelom Leuk"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000413","article-title":"Cerebrospinal fluid penetrance of daratumumab in leptomeningeal multiple myeloma","author":"Zajec","year":"2020","journal-title":"Hemasphere"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1451","article-title":"Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab","volume":"6","author":"Elhassadi","year":"2018","journal-title":"Clin Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3970169","article-title":"Multiple myeloma of the central nervous system: 13 cases and review of the literature","volume":"2018","author":"Varga","year":"2018","journal-title":"J Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/neuonc\/nou303","article-title":"Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma","volume":"17","author":"Green","year":"2015","journal-title":"Dev Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137197","article-title":"Venetoclax crosses the blood brain barrier: a pharmacokinetic analysis of the cerebrospinal fluid in pediatric leukemia patients","volume":"136","author":"Salem","year":"2020","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1276295","article-title":"Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case","volume":"14","author":"Mutlu","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/1040-8428(92)90092-5","article-title":"Pharmacology of agents used in bone marrow transplant conditioning regimens","volume":"13","author":"Wiebe","year":"1992","journal-title":"Crit Rev Oncol Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1630","article-title":"Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient","volume":"6","author":"Camus","year":"2018","journal-title":"Clin Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.959949","article-title":"Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)","volume":"12","author":"Song","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.755584","article-title":"Successful BCMA CAR-T therapy for multiple myeloma with central nervous system involvement manifesting as cauda equina syndrome\u2014A wandering road to remission","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.854448","article-title":"Clinical outcomes of BCMA CAR-T cells in a multiple myeloma patient with central nervous system invasion","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/cji.0000000000000391","article-title":"BCMA CAR-T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T06:09:59Z","timestamp":1751954999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1628297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1628297"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1628297","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"article-number":"1628297"}}